Switzerland's Unilabs diagnostic services provider and Israel's Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-powered cancer diagnostics, have signed a deal to implement Ibex's AI platform in pathology labs across Europe, the companies announced Wednesday.
Follow Israel Hayom on Facebook and Twitter
Starting with a national rollout in Sweden, Unilabs will then bring Ibex's platform to 16 countries. Unilabs is the first pan-European diagnostics provider to deploy Ibex's multi-tissue AI-powered Galen platform, providing patients and physicians with a faster and more accurate diagnosis, facilitating prompt, targeted cancer treatment when it is most needed.
"This cutting-edge AI technology will help our teams quickly prioritize urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes," said Dr. Christian Rebhan, Unilabs' Chief Medical & Operations Officer. "When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs' pioneering role in digital pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe."
"Ibex is transforming cancer with innovative AI solutions across the diagnostic pathway," said Joseph Mossel, Chief Executive Officer and co-founder of Ibex Medical Analytics. "We are excited to partner with Unilabs to deploy our AI solutions and empower their pathologists with faster turnaround times and quality diagnosis. This cooperation follows a thorough evaluation of our technology at Unilabs, and demonstrates the robustness and utility of our platform for everyday clinical practice."
